Cymabay Therapeutics Inc Quick Ratio (CBAY) starting from the fourth quarter 2023 to fourth quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Cymabay Therapeutics Inc   (NASDAQ: CBAY)

Cymabay Therapeutics Inc 's Quick Ratio

CBAY's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2023, Quick Ratio fell to 10.7 above Cymabay Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 97 other companies have achieved higher Quick Ratio than Cymabay Therapeutics Inc in fourth quarter 2023. While Quick Ratio total ranking in the fourth quarter 2023 has deteriorated compared to the prior quarter from 68 to 403.

Explain Quick Ratio?
How much Cash & cash equivalents CBAY´s has?
What are CBAY´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CBAY Quick Ratio (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3		 (Jun 30 2023)
Q2		 (Mar 31 2023)
Q1		 (Dec 31 2022)
Q4
Y / Y Current Liabilities Change 138.61 % 8.81 % 3.95 % 191.58 % -15.93 %
Y / Y Cash & cash equivalent Change 191 % 186.01 % 30.49 % 25.35 % -27.37 %
Quick Ratio MRQ 10.7 31.72 16.38 5.77 8.77
CBAY's Total Ranking # 403 # 68 # 170 # 599 # 346
Seq. Current Liabilities Change 166.38 % 5.94 % -68.11 % 165.11 % 21.48 %
Seq. Cash & cash equivalent Change -10.15 % 105.19 % -9.53 % 74.46 % -11.69 %



Quick Ratio fourth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 98
Healthcare Sector # 166
Overall Market # 403


Quick Ratio Statistics
High Average Low
31.72 9.74 0.45
(Sep 30 2023)   (Dec 31 2012)




Financial Statements
Cymabay Therapeutics Inc 's Current Liabilities $ 37 Millions Visit CBAY's Balance sheet
Cymabay Therapeutics Inc 's Cash & cash equivalent $ 394 Millions Visit CBAY's Balance sheet
Source of CBAY's Sales Visit CBAY's Sales by Geography


Cumulative Cymabay Therapeutics Inc 's Quick Ratio

CBAY's Quick Ratio for the trailling 12 Months

CBAY Quick Ratio

 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months		 (Jun 30 2023)
12 Months		 (Mar 31 2023)
12 Months		 (Dec 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 91.17 % 44.36 % 44.86 % 53.75 % 16.55 %
Y / Y Cash & cash equivalent TTM Growth 100.09 % 47.96 % 13.23 % 15.82 % 20.57 %
Quick Ratio TTM 12.26 12.3 9 8.44 11.71
Total Ranking TTM # 3310 # 3074 # 2875 # 466 # 2703
Seq. Current Liabilities TTM Growth 25.7 % 1.36 % 0.61 % 49.12 % -5.07 %
Seq. Cash & cash equivalent TTM Growth 25.26 % 38.61 % 7.25 % 7.45 % -7.37 %

Quick ratio ranking by company, industry and sector >> Back to CBAY Financial Strength Comparisons >> Go to Compare CBAY Quick Ratio to its Competitors

On the trailing twelve months basis Due to in Current Liabilities in the Q4 2023 to $36.84 millions, cumulative Quick Ratio decreased to 12.26 above the CBAY average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 463 other companies have achieved higher Quick Ratio than Cymabay Therapeutics Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2023 from 3074 to 3310.

Explain Quick Ratio?
How much Cash & cash equivalents CBAY´s has?
What are CBAY´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 464
Healthcare Sector # 918
Within the Market # 3310


trailing twelve months Quick Ratio Statistics
High Average Low
15.23 11.41 4.51
(Jun 30 2019)   (Dec 31 2017)




Companies with similar Quick Ratio in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2023 MRQ Cash & cash equivalentDec 31 2023 MRQ Current Liabilities
Design Therapeutics Inc   29.29 $ 281.798  Millions$ 9.622  Millions
Bicara Therapeutics Inc   28.62 $ 230.440  Millions$ 8.053  Millions
Morphic Holding inc   28.43 $ 704.349  Millions$ 24.776  Millions
Roivant Sciences Ltd   27.24 $ 6,670.810  Millions$ 244.899  Millions
Lixte Biotechnology Holdings Inc   26.81 $ 4.203  Millions$ 0.157  Millions
Upstream Bio Inc   26.41 $ 109.810  Millions$ 4.158  Millions
Karuna Therapeutics Inc   26.10 $ 1,262.813  Millions$ 48.392  Millions
Crinetics Pharmaceuticals Inc   26.04 $ 1,144.421  Millions$ 43.942  Millions
Akero Therapeutics Inc   24.42 $ 550.010  Millions$ 22.522  Millions
Belite Bio Inc  24.27 $ 88.157  Millions$ 3.633  Millions
Xenon Pharmaceuticals Inc   23.40 $ 638.082  Millions$ 27.273  Millions
Immunome Inc   23.37 $ 142.151  Millions$ 6.082  Millions
Anixa Biosciences Inc   23.06 $ 46.773  Millions$ 2.028  Millions
Nuvalent Inc   22.62 $ 719.905  Millions$ 31.823  Millions
Janux Therapeutics Inc   22.31 $ 344.028  Millions$ 15.422  Millions
Xbiotech Inc   22.25 $ 200.023  Millions$ 8.990  Millions
Astria Therapeutics Inc   21.97 $ 246.530  Millions$ 11.221  Millions
Pliant Therapeutics Inc   21.81 $ 495.544  Millions$ 22.724  Millions
Annexon Inc   21.11 $ 259.716  Millions$ 12.305  Millions
Spyre Therapeutics Inc   20.83 $ 339.277  Millions$ 16.290  Millions
Cadrenal Therapeutics Inc  20.72 $ 16.690  Millions$ 0.806  Millions
Ideaya Biosciences Inc   20.71 $ 525.114  Millions$ 25.354  Millions
Shattuck Labs Inc   20.29 $ 175.284  Millions$ 8.639  Millions
Rezolute Inc   19.60 $ 101.896  Millions$ 5.200  Millions
Diamedica Therapeutics Inc   19.57 $ 52.895  Millions$ 2.703  Millions
89bio Inc   19.55 $ 578.870  Millions$ 29.611  Millions
Lantern Pharma Inc   19.25 $ 51.555  Millions$ 2.678  Millions
Viking Therapeutics Inc   19.25 $ 362.079  Millions$ 18.811  Millions
Edgewise Therapeutics inc   18.98 $ 318.393  Millions$ 16.771  Millions
Disc Medicine Inc   18.53 $ 360.382  Millions$ 19.453  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.